<DOC>
	<DOCNO>NCT01215734</DOCNO>
	<brief_summary>Hypothesis 1 : The safety profile adult allogeneic stem cell hematopoietic transplant ( SCT ) recipients high dose ( HD ) trivalent inactivate influenza vaccine ( TIV ) significantly different adult stem cell transplant recipient receive standard dose ( SD ) TIV . - Specific Aim 1 : To compare safety profile high dose trivalent inactivate influenza vaccine standard dose trivalent inactivate influenza vaccine adult hematopoietic stem cell transplant recipient . Hypothesis 2 : Adult stem cell transplant recipient receive high dose trivalent influenza vaccine great frequency ( least 4-fold ) rise antibody titer influenza antigen compare receive standard dose trivalent influenza vaccine . - Specific Aim 2 : To compare humoral immune response adult hematopoietic stem cell transplant recipient influenza virus antigen include trivalent influenza vaccine high dose standard dose trivalent influenza vaccine .</brief_summary>
	<brief_title>Standard vs High-Dose Trivalent Inactivated Flu Vaccine Adult Hematopoetic Stem Cell Transplant ( HSCT ) Recipients</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Allogeneic hematopoietic stem cell transplant recipient &gt; 6 posttransplant great equal 18 year age Available duration study If patient immunosuppressive therapy treatment graft versus host disease ( GVHD ) : stable dos least 4 week taper dos eligible . History hypersensitivity previous influenza vaccination hypersensitivity eggs/egg protein History GuillainBarre syndrome Evidence hematologic malignancy disease relapse posttransplant ( mixed chimerisms molecular evidence disease permit ) Nonallogeneic ( e.g . autologous ) hematopoietic SCT recipient History receive 2011 2012 influenza vaccine History proven influenza disease September 1 , 2011 . Pregnant female Have condition would , opinion site investigator , place unacceptable risk injury render unable meet requirement protocol Have condition investigator believe may interfere successful completion study Platelet count le 50,000 cells/Î¼L History know infection HIV , Hepatitis B Hepatitis C History know latex hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>